source
- Regeneron defends M&A stance as cash hoard reaches $18 billion amid trial setbacksAnalysts on Regeneron's second‑quarter earnings call questioned the company's lack of merger and acquisition activity, pointing to an $18 billion cash reserve and recent clinical trial setbacks. C…
- Rising oil prices could lift manufacturing costs of an HIV drug, Unitaid report saysRising oil prices, driven in part by geopolitical tensions, have raised concerns about the stability of medicine supply chains. Analysts note that higher energy costs can translate into increased p…